Universal Ibogaine Inc (TSE:IBO) has released an update.
Universal Ibogaine Inc. is advancing its mission to revolutionize addiction treatment by engaging Changemark Research + Evaluation Ltd. to facilitate a Clinical Trial Application with Health Canada for ibogaine use in opioid addiction. With a 4 to 6 month project timeframe, UI aims to finalize study design for a trial that could significantly impact addiction treatment protocols. The company’s broader vision includes a state-of-the-art holistic addiction treatment protocol at its Kelburn Recovery Centre.
For further insights into TSE:IBO stock, check out TipRanks’ Stock Analysis page.
